Status:
COMPLETED
XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA-Phase 1)
Lead Sponsor:
Abbott Medical Devices
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
Brief Summary
XIENCE V USA is a prospective, multi-center, multi-cohort post-approval study. The objectives of this study are * To evaluate XIENCE V EECSS continued safety and effectiveness during commercial use i...
Detailed Description
Study Phase I is from index procedure to 1 year. This prospective, open-label, multi-center, observational, single-arm study is designed to evaluate XIENCE V EECSS safety and effectiveness in real wor...
Eligibility Criteria
Inclusion
- The patient agrees to participate in this study by signing the Institutional Review Board approved informed consent form.
Exclusion
- The inability to obtain an informed consent.
- Age limit is determined by investigator.
- There are no angiographic inclusion or exclusion criteria for this study.
Key Trial Info
Start Date :
July 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2011
Estimated Enrollment :
8053 Patients enrolled
Trial Details
Trial ID
NCT00676520
Start Date
July 1 2008
End Date
March 1 2011
Last Update
November 20 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Abbott Vascular
Santa Clara, California, United States, 95054